Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer
about
Immune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumDendritic Cells in Oncolytic Virus-Based Anti-Cancer TherapySignaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated MacrophagesTumor-infiltrating dendritic cells in cancer pathogenesisImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerHarnessing immunosurveillance: current developments and future directions in cancer immunotherapyTumor infiltrating lymphocytes in ovarian cancerPhenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancyTargeted immune therapy of ovarian cancerRegulatory dendritic cells: there is more than just immune activationOrchestration of angiogenesis by immune cellsArginine deprivation and immune suppression in a mouse model of Alzheimer's diseaseMelanoma-infiltrating dendritic cells: Limitations and opportunities of mouse modelsPathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancerCombinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinNatural IgM Switches the Function of Lipopolysaccharide-Activated Murine Bone Marrow-Derived Dendritic Cells to a Regulatory Dendritic Cell That Suppresses Innate InflammationThe expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphomaPD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerAccumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.Murine lung cancer induces generalized T-cell exhaustion.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κBIL-27 induces the expression of IDO and PD-L1 in human cancer cells.PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunityRole of dendritic cells in the regulation of antitumor immunityDual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.Aiming to immune elimination of ovarian cancer stem cellsStimulation through CD40 and TLR-4 Is an Effective Host Directed Therapy against Mycobacterium tuberculosis.Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse modelTherapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerOvarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase.Tumor associated regulatory dendritic cells.Dendritic cells and their role in tumor immunosurveillance.Dendritic cell immunotherapy in ovarian cancer.Tumor-altered dendritic cell function: implications for anti-tumor immunity.
P2860
Q26765459-185FFAB8-3D8B-4CD3-9D6F-F527FC6356B0Q26774345-80B82907-4FF8-4547-AC6B-05AEE29A59E0Q26783748-4592D25F-DE33-480F-B33A-8FE40CEBEE9CQ26861633-E47FEB2B-D83D-4000-9BF0-2C6AE834C7FBQ26996829-55F04F25-54B8-4292-8ECD-71321DC7EE59Q27021570-1B20DB00-7422-4F0C-8B91-9F8E0268DD21Q27021878-7FBA829E-0640-49FD-8422-BFA6D4096639Q27346770-045A4D58-C1C1-4032-88C5-8F626236C6C3Q28082828-97BF9D80-D85F-4681-94AE-2269A6FC1EEBQ28388235-DE9EA88D-6FEE-4608-B51C-474C94571415Q28389236-BEF18F34-99E6-4BA9-BF93-70EFD1542CD9Q28391826-64582F51-8A71-434C-A1FD-76BA3FC544CEQ28392156-2E575D6F-0272-48FE-8D4D-B30BBB22F18BQ28392626-E69C2288-3103-49B4-B3E6-8CE9ABF86982Q28537820-D0F1AA90-9DAD-4999-BA5A-A2CBE09719BBQ30278437-79816773-171C-49F6-BC26-D33AD04B82F0Q33597192-E8794174-7E50-4163-AA04-E2E20A26B474Q33648598-C6E668B4-E6C3-4BAE-986C-444F70DACD64Q33659166-9BD121F7-5DF0-4457-9C82-9B636FBDB9EBQ35036388-6C53D3AE-9287-4D4B-A5F7-0ECC30ED7822Q35562860-EEACC045-67C6-4F78-8914-30124A8C9B5EQ36021163-8D557938-3DCB-4039-8076-204E02CF9E8EQ36267621-657162EF-432B-483F-8E1B-F85AF2AE8BE0Q36295211-04D71F1A-84FD-4CF2-A3A8-127F8DC0B9DFQ36471523-0C77D68F-3F58-4BE2-8DB0-2D7328F87B18Q36685395-3D27F8CC-5744-4047-BF7C-1AE9F622BBB9Q36821174-92A89208-CCBA-47F6-901F-71CC50E49907Q36845842-949A903A-9A8D-44E6-8862-153D70A41B83Q36941194-1FBF9CDA-87DF-465C-85C2-0840F0334824Q37017085-EE36F56B-5FB3-4197-B391-BFA62C86A9F2Q37224568-215F3A4C-D89A-4B75-A8D3-5DA5E270DE04Q37266548-1F2BC7BE-6EC4-47DA-8862-BE6F8C73AF6EQ37284865-08F3105A-E7FC-477F-B708-DCF4297A7C8CQ37355822-998A9BE8-319A-4DE9-8AA2-8E35BD668BD2Q37365673-411FD10A-8FC9-4AC0-B441-109C608ACFAAQ37637888-99505977-80B7-4CB9-B250-F705AE24B6D0Q37993359-F659922D-62FE-41BF-B545-04AC6308907DQ38021625-B58656B7-6A12-49F8-B1CD-6C9D906B1278Q38069183-59F124AB-BFC9-413D-A148-5D4E8969BA3CQ38123166-8D1454E8-66D2-4979-83FB-58D7FC46E7B2
P2860
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Tumor-infiltrating programmed ...... suppression in ovarian cancer
@ast
Tumor-infiltrating programmed ...... suppression in ovarian cancer
@en
type
label
Tumor-infiltrating programmed ...... suppression in ovarian cancer
@ast
Tumor-infiltrating programmed ...... suppression in ovarian cancer
@en
prefLabel
Tumor-infiltrating programmed ...... suppression in ovarian cancer
@ast
Tumor-infiltrating programmed ...... suppression in ovarian cancer
@en
P2093
P2860
P356
P1476
Tumor-infiltrating programmed ...... suppression in ovarian cancer
@en
P2093
Courtney L Erskine
Ellen L Goode
Haidong Dong
James Krempski
Keith L Knutson
Kimberly R Kalli
Lavakumar Karyampudi
Lynn Hartmann
Marshall D Behrens
P2860
P304
P356
10.4049/JIMMUNOL.1100274
P407
P577
2011-05-06T00:00:00Z